Abstract
Genome-wide association studies (GWAS) identify genetic variants underlying complex traits but are limited by stringent genome-wide significance thresholds. Here we dramatically relax GWAS stringency by orders of magnitude and apply GRIN (Gene set Refinement through Interacting Networks), which increases confidence in the expanded gene set by retaining genes strongly connected by biological networks from diverse lines of evidence. From multiple GWAS summary statistics of suicide attempt, a complex psychiatric phenotype, GRIN identified additional genes that replicated across independent cohorts and retained genes that were more biologically interrelated despite a relaxed significance threshold. We present a conceptual model of how these retained genes interact through neurobiological pathways to influence suicidal behavior and identify existing drugs associated with these pathways that would not have been identified under traditional GWAS thresholds. We demonstrate that GRIN is a useful community resource for improving the signal to noise ratio of GWAS results.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was sponsored by MVP CHAMPION (DAJ), NIH grants DA041913 (DAJ), DA051908 (DAJ), MH116269 (DMR), MH121455 (DMR), Brain & Behavior Research Foundation (NARSAD Young Investigator Award No. 29551 [NM]), Department of Veterans Affairs (VA) Clinical Science Research and Development (CSR&D) grants lK6BX003777 (JCB, NAK, DWO) and lK6BX003777 (JCB), and the VA Million Veteran Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All subjects from the Million Veteran Program provided informed consent and the activities used to generate the genome-wide association study (GWAS) summary statistics were approved by the Department of Veterans Affairs Central Institutional Review Board. The following Institutional Review Boards approved the activities used to generate the GWAS summary statistics for the International Suicide Genetics Consortium: University of North Carolina at Chapel Hill; University of Oxford; Emory University and Grady Research Oversight Committee; University of Michigan IRB; Medical Faculty Mannheim, Heidelberg University; Charite; Berlin; State Chamber of Physicians of Rhineland Palatinate Generic approval from the NHS National Research Ethics Service (approval letter dated 13 May 2016, Ref 16/NW/0274); National Taiwan University Hospital; Danish Regional Ethics Committee; Janssen Research & Development, LLC, institutional review board or human subjects board at each site; prospective collection of normal control samples for research by BioIV was approved by Schulman IR; Research Ethics Committee at the Karolinska Institute (#97-188) and Ministry of Health in Ukraine; The QIMR Berghofer Medical Research Institute-Human Research Ethics Committee (QIMR Berghofer-HREC); Yale: Human Research Protection Program (HRPP); MUSC: Medical University of South Carolina Institutional Review Board for Human Research; Penn: University of Pennsylvania Office of Regulatory Affairs; McLean: McLean Hospital Institutional Review Board; UConn: University of Connecticut Institutional Review Board; Yale: Human Research Protection Program (HRPP); New York State Psychiatric Institute IRB; University of Utah IRB; Utah State Health Department IRB; Intermountain Health IRB; The Ethics Committee for Genetic Studies of Kobe University and RIKEN.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This manuscript has been authored by UT-Battelle, LLC under Contract No. DE-AC05-00OR22725 with the U.S. Department of Energy. The United States Government retains and the publisher, by accepting the article for publication, acknowledges that the United States Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes. The Department of Energy will provide public access to these results of federally sponsored research in accordance with the DOE Public Access Plan (http://energy.gov/downloads/doe-public-access-plan).
Data Availability
GWAS summary statistics from the Million Veteran Program used in this study will be made available on the NIH database of Genotypes and Phenotypes (dbGaP) under accession ID phs001672.v1.p. Summary statistics from the International Suicide Genetics Consortium are available at https://tinyurl.com/ISGC2021. GRIN code and the multiplex network used for this study is located at https://github.com/sullivanka/GRIN.
